Glucophage stilldriving Merck KGaA
Reporting what it describes as its "best-ever" results, Germany's Merck KGaA says that second-quarter 2001 sales increased 16% to 1.95 billion euros ($1.69 billion), mainly driven by real growth (13%) rather than currency effects (2.6%). Operating income for the quarter was 34% higher at 249 million euros and net income soared 87% to 96 million euros. The group's tax rate fell to 47% in the period from 54% in the like, 2000 quarter.
Pharmaceuticals, and particularly the Glucophage (metformin) antidiabetes franchise, which is co-marketed with Bristol-Myers Squibb, were the main drivers of Merck's sales growth. Total turnover rose 19% to 871 million euros, with operating profits for this business rising 40% to 162 million euros. Pharmaceuticals contributed 45% of sales and 65% of operating profits to the group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze